|
270 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
39 Trials |
|
5519 News |
|
| «12...4567891011121314...110111» |
- | Trial completion, Preclinical, Enrollment change, Trial primary completion date: NXGeM: Comparison of Culture Media for in Vitro Embryo Development (clinicaltrials.gov) - Dec 27, 2017
P=N/A, N=45, Completed, Sponsor: Ovation Fertility
Recruiting --> Completed | N=300 --> 45 | Trial primary completion date: May 2018 --> Dec 2017
- || Biomarker, Trial primary completion date, Tumor cell: Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass. (clinicaltrials.gov) - Dec 27, 2017
P=N/A, N=204, Active, not recruiting, Sponsor: Angle plc
Recruiting --> Completed | N=300 --> 45 | Trial primary completion date: May 2018 --> Dec 2017 Trial primary completion date: Jul 2017 --> Oct 2017
- | Enrollment change, Trial termination: FertilEX: Improved Fertility After Exercise in Overweight/Obese Women (clinicaltrials.gov) - Dec 21, 2017
P=N/A, N=18, Terminated, Sponsor: Norwegian University of Science and Technology
Trial primary completion date: Jul 2017 --> Oct 2017 N=140 --> 18 | Recruiting --> Terminated; Enrollment proceeded to slowly
- || zabedosertib (BAY1834845) / Bayer
Enrollment closed, Trial primary completion date: First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845 (clinicaltrials.gov) - Dec 21, 2017
P1, N=70, Active, not recruiting, Sponsor: Bayer
N=140 --> 18 | Recruiting --> Terminated; Enrollment proceeded to slowly Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> Nov 2017
- | Ophena (ospemifene) / Shionogi
Enrollment change, Trial initiation date, Trial termination: Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction (clinicaltrials.gov) - Dec 20, 2017
P4, N=1, Terminated, Sponsor: Emory University
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> Nov 2017 N=104 --> 1 | Initiation date: Jan 2017 --> Jun 2017 | Recruiting --> Terminated; Obstacles with recruitment
- | New trial: ERROR: Endometrioma Related Reduced Ovarian Reserve (clinicaltrials.gov) - Dec 20, 2017
P=N/A, N=80, Completed, Sponsor: Uludag University
- | New trial: Aspiring to Awesome- Patient Preference Privacy Selections in EMR (clinicaltrials.gov) - Dec 20, 2017
P=N/A, N=136, Completed, Sponsor: Indiana University
- | New trial: The Impact of Distress on the IVF Outcome (clinicaltrials.gov) - Dec 20, 2017
P=N/A, N=143, Completed, Sponsor: Boston IVF
- | New P1/2 trial: Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Dec 20, 2017
P1/2, N=36, Completed, Sponsor: Milton S. Hershey Medical Center
- | Enrollment open, Trial primary completion date: HPV Self-Sampling for Cervical Cancer Screening Among Lesbian, Bisexual, and Queer (LBQ) Women (clinicaltrials.gov) - Dec 20, 2017
P=N/A, N=30, Recruiting, Sponsor: University of Miami
N=104 --> 1 | Initiation date: Jan 2017 --> Jun 2017 | Recruiting --> Terminated; Obstacles with recruitment Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2017 --> Jun 2018
- | New trial: Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=1181, Completed, Sponsor: University of Pennsylvania
- | New trial: CONRADBV: Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=35, Completed, Sponsor: CONRAD
- | carboplatin / Generic mfg., paclitaxel / Generic mfg., dasatinib / Generic mfg.
New P1 trial, Metastases: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (clinicaltrials.gov) - Dec 19, 2017
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | Enrollment change, Trial termination: FLT PET Imaging for Cervical Cancer (clinicaltrials.gov) - Dec 19, 2017
P2, N=6, Terminated, Sponsor: University of Iowa
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2017 --> Jun 2018 N=30 --> 6 | Active, not recruiting --> Terminated; Study was closed and reopened as NCT01717391
- | Phase classification: Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=1181, Completed, Sponsor: University of Pennsylvania
N=30 --> 6 | Active, not recruiting --> Terminated; Study was closed and reopened as NCT01717391 Phase classification: P2 --> P=N/A
- | Enrollment change: ERROR: Endometrioma Related Reduced Ovarian Reserve (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=80, Completed, Sponsor: Uludag University
Phase classification: P2 --> P=N/A N=62 --> 80
- Trial primary completion date: INREG 1: Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule (clinicaltrials.gov) - Dec 18, 2017
P=N/A, N=20, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
N=62 --> 80 Trial primary completion date: Jan 2018 --> Jun 2018
- | Trial completion: Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis (clinicaltrials.gov) - Dec 18, 2017
P2, N=109, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jan 2018 --> Jun 2018 Recruiting --> Completed
- | letrozole / Generic mfg.
Enrollment closed: RIOT-B: Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles (clinicaltrials.gov) - Dec 15, 2017
P2/3, N=33, Active, not recruiting, Sponsor: Sven O. Skouby
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| TroVax (MVA 5T4) / Oxford Biomedica
Enrollment closed: TRIOC: The Activity of TroVax (clinicaltrials.gov) - Dec 15, 2017
P2, N=97, Active, not recruiting, Sponsor: University College, London
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Trial initiation date, Trial primary completion date: Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis (clinicaltrials.gov) - Dec 14, 2017
P3, N=300, Not yet recruiting, Sponsor: Medinova AG
Recruiting --> Active, not recruiting Initiation date: May 2017 --> Dec 2018 | Trial primary completion date: May 2018 --> Dec 2019
- ||| CRS-207 / Novartis
Enrollment closed, Combination therapy: SEASCAPE: Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer (clinicaltrials.gov) - Dec 14, 2017
P1/2, N=126, Active, not recruiting, Sponsor: Aduro Biotech, Inc.
Initiation date: May 2017 --> Dec 2018 | Trial primary completion date: May 2018 --> Dec 2019 Recruiting --> Active, not recruiting
- | Trial completion: Effect of Sorting of Apoptotic Spermatozoa on the Outcome of Assisted Reproduction (clinicaltrials.gov) - Dec 12, 2017
P=N/A, N=100, Completed, Sponsor: University Hospital, Basel, Switzerland
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | carboplatin / Generic mfg., paclitaxel / Generic mfg., dasatinib / Generic mfg.
Trial primary completion date, Metastases: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (clinicaltrials.gov) - Dec 12, 2017
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Dec 2015
- | Enrollment change, Trial termination: Cervical Cancer Screening Project Part C (clinicaltrials.gov) - Dec 12, 2017
P=N/A, N=10, Terminated, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Trial primary completion date: Jul 2015 --> Dec 2015 N=60 --> 10 | Recruiting --> Terminated; Investigator left University No results are possible
- | Trial completion: A Mind-body Intervention to Improve Body and/or Self Image (clinicaltrials.gov) - Dec 12, 2017
P2, N=97, Completed, Sponsor: University of Michigan
N=60 --> 10 | Recruiting --> Terminated; Investigator left University No results are possible Recruiting --> Completed
- | Phase classification, Preclinical, Enrollment change, Trial termination, Trial primary completion date: Use of Nitric Oxide Metabolites for Predicting Embryo Quality in In-Vitro Fertilization (IVF) (clinicaltrials.gov) - Dec 11, 2017
P=N/A, N=2, Terminated, Sponsor: Johns Hopkins University
Recruiting --> Completed Phase classification: P2/3 --> P=N/A | N=250 --> 2 | Suspended --> Terminated | Trial primary completion date: Jan 2012 --> Oct 2009; difficulty with recruitment
- | Enrollment open, Trial primary completion date: Fermented Wheat Germ Extract in Women With Ovarian Cancer (clinicaltrials.gov) - Dec 11, 2017
P=N/A, N=20, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Phase classification: P2/3 --> P=N/A | N=250 --> 2 | Suspended --> Terminated | Trial primary completion date: Jan 2012 --> Oct 2009; difficulty with recruitment Active, not recruiting --> Recruiting | Trial primary completion date: Aug 2017 --> Dec 2018
- | Trial completion, MRI: Preoperative Staging of Endometriosis With MRI (clinicaltrials.gov) - Dec 8, 2017
P=N/A, N=120, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
Active, not recruiting --> Recruiting | Trial primary completion date: Aug 2017 --> Dec 2018 Active, not recruiting --> Completed
- ||| Trial completion, Trial primary completion date: Detection of Chlamydia (CT) and Gonorrhea (NG) (clinicaltrials.gov) - Dec 7, 2017
P=N/A, N=700, Completed, Sponsor: Meridian Bioscience, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Sep 2014
- ||||||| VivaGel (astodrimer vaginal) / Starpharma
Trial completion: Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV) (clinicaltrials.gov) - Dec 7, 2017
P3, N=637, Completed, Sponsor: Starpharma Pty Ltd
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Sep 2014 Active, not recruiting --> Completed
- | Mifeprex (mifepristone) / Danco Laboratories
Trial primary completion date, Metastases: Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 7, 2017
P1, N=31, Active, not recruiting, Sponsor: University of Chicago
Active, not recruiting --> Completed Trial primary completion date: Nov 2017 --> Jun 2018
- | Trial completion, Enrollment change, Trial primary completion date: Biobehavioral Intervention in Gynecologic Oncology Patients (clinicaltrials.gov) - Dec 5, 2017
P2, N=6, Completed, Sponsor: Rachel Miller
Trial primary completion date: Nov 2017 --> Jun 2018 Recruiting --> Completed | N=30 --> 6 | Trial primary completion date: Dec 2017 --> May 2017
- | Enrollment closed, Trial primary completion date: STI Screening as a Combined HIV Prevention Platform for MSM in Peru (clinicaltrials.gov) - Dec 4, 2017
P=N/A, N=150, Active, not recruiting, Sponsor: University of California, Los Angeles
Recruiting --> Completed | N=30 --> 6 | Trial primary completion date: Dec 2017 --> May 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Jun 2018
- | Trial completion: SeTPAT: Treponema Pallidum-specific Proteomic Changes in Patients With Incident Syphilis Infection (clinicaltrials.gov) - Nov 30, 2017
P=N/A, N=150, Completed, Sponsor: Institute of Tropical Medicine, Belgium
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Jun 2018 Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: DNA Array Analysis of Patients With Cervical Cancer (clinicaltrials.gov) - Nov 30, 2017
P=N/A, N=18, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2019 --> Nov 2017
- | Norditropin (somatropin) / Novo Nordisk
Trial initiation date: Long Protocol and Growth Hormone in Poor Responders (clinicaltrials.gov) - Nov 29, 2017
P2, N=240, Completed, Sponsor: Woman's Health University Hospital, Egypt
Active, not recruiting --> Completed | Trial primary completion date: Dec 2019 --> Nov 2017 Initiation date: Jan 2016 --> Mar 2015
- | Menopur (menotropin) / Ferring
Trial primary completion date: HRT Versus MOS for Endometrial Preparation Prior to FET in PCOS Patients (clinicaltrials.gov) - Nov 28, 2017
P4, N=150, Recruiting, Sponsor: Mansoura University
Initiation date: Jan 2016 --> Mar 2015 Trial primary completion date: Jun 2017 --> Nov 2017
- | Norditropin (somatropin) / Novo Nordisk
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Long Protocol and Growth Hormone in Poor Responders (clinicaltrials.gov) - Nov 28, 2017
P2, N=240, Completed, Sponsor: Woman's Health University Hospital, Egypt
Trial primary completion date: Jun 2017 --> Nov 2017 Recruiting --> Completed | N=150 --> 240 | Initiation date: Jan 2015 --> Jan 2016 | Trial primary completion date: Nov 2015 --> Nov 2017
- |||| metformin hydrochloride extended release / Generic mfg.
Trial primary completion date: Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Nov 27, 2017
P3, N=124, Recruiting, Sponsor: Dexa Medica Group
Recruiting --> Completed | N=150 --> 240 | Initiation date: Jan 2015 --> Jan 2016 | Trial primary completion date: Nov 2015 --> Nov 2017 Trial primary completion date: Dec 2017 --> Apr 2018
- | Trial completion, Trial primary completion date: Microfinance and Health Intervention Trial for Youth in Dar es Salaam, Tanzania (clinicaltrials.gov) - Nov 27, 2017
P=N/A, N=2623, Completed, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: Dec 2017 --> Apr 2018 Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017
- | zoledronic acid / Generic mfg.
Phase classification: Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (clinicaltrials.gov) - Nov 24, 2017
P1, N=12, Terminated, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017 Phase classification: P2 --> P1
- | Enrollment change, Trial primary completion date, HEOR: A Survivorship Care Plan for Gynaecological Cancer Patients (clinicaltrials.gov) - Nov 24, 2017
P=N/A, N=150, Completed, Sponsor: Royal Marsden NHS Foundation Trust
Phase classification: P2 --> P1 N=75 --> 150 | Trial primary completion date: Aug 2013 --> Mar 2014
- | Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Enrollment change, Trial primary completion date: MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors (clinicaltrials.gov) - Nov 24, 2017
P2, N=4, Active, not recruiting, Sponsor: Washington University School of Medicine
N=75 --> 150 | Trial primary completion date: Aug 2013 --> Mar 2014 Recruiting --> Active, not recruiting | N=136 --> 4 | Trial primary completion date: Dec 2019 --> Sep 2017
- | Trial completion: LNGIUSAD: LNG-IUS for Treatment of Dysmenorrhea (clinicaltrials.gov) - Nov 22, 2017
P2, N=62, Completed, Sponsor: Omar Mamdouh Shaaban
Recruiting --> Active, not recruiting | N=136 --> 4 | Trial primary completion date: Dec 2019 --> Sep 2017 Active, not recruiting --> Completed
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: CRUSH: Connecting Resources for Urban Sexual Health (clinicaltrials.gov) - Nov 21, 2017
P=N/A, N=380, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Phase classification: Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects (clinicaltrials.gov) - Nov 21, 2017
P=N/A, N=15, Completed, Sponsor: Alma Lasers Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Phase classification: P1 --> PN/A
- | veliparib (ABT-888) / AbbVie
Trial completion, Trial primary completion date, Combination therapy, PARP Biomarker, Metastases: Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer (clinicaltrials.gov) - Nov 21, 2017
P1, N=34, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Phase classification: P1 --> PN/A Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Nov 2016
- pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg.
Enrollment change, Trial withdrawal: Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - Nov 20, 2017
P1/2, N=0, Withdrawn, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Nov 2016 N=61 --> 0 | Completed --> Withdrawn
- | cisplatin / Generic mfg.
Trial completion, Surgery, Metastases: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva (clinicaltrials.gov) - Nov 19, 2017
P2, N=61, Completed, Sponsor: Gynecologic Oncology Group
N=61 --> 0 | Completed --> Withdrawn Active, not recruiting --> Completed